Eetu Heervä1, Maija Lavonius2, Panu Jaakkola3, Heikki Minn4, Raija Ristamäki4. 1. Department of Oncology, University of Turku and Turku University Hospital, Hameentie 11, 20521, Turku, Finland. eaheer@utu.fi. 2. Department of Digestive Surgery, University of Turku and Turku University Hospital, Hameentie 11, 20521, Turku, Finland. 3. Department of Oncology, University of Turku and Turku University Hospital and Turku University Hospital Cancer Centre, Hameentie 11, 20521, Turku, Finland. 4. Department of Oncology, University of Turku and Turku University Hospital, Hameentie 11, 20521, Turku, Finland.
Abstract
PURPOSE: Treatment for patients with metastatic colorectal cancer is chemotherapy commonly combined with monoclonal antibodies against vascular endothelial growth factor (bevacizumab) or epidermal growth factor receptor (cetuximab or panitumumab), the efficacy of which has been proven in randomized controlled trials. The objective of the current retrospective study was to analyze the impact of targeted therapy, adverse events, and dose reduction on overall survival (OS) and metastasis resection rates. METHODS: A hospital-based electronic informatics center was used to gather clinical data and outcome information in a "real-life" setting in a single academic hospital. A total of 178 patients were included in 2010-2013. RESULTS: In patients whose tumors expressed the KRAS wild type, the longest median OS was observed with irinotecan-based chemotherapy combined with bevacizumab (38 months), or with cetuximab (41 months). In the KRAS-mutated group, the longest median OS was observed with oxaliplatin with or without bevacizumab (34 months). Beneficial liver metastasis resections were observed in 12 out of 20 patients. Patients with KRAS wild-type tumors who received cetuximab were the most likely to undergo surgery. Age was a negative predictor of OS. Patients whose chemotherapy dose was reduced to below 80% had lower OS compared to those remaining above 80%. Treatment delays in chemotherapy did not affect OS. Pulmonary embolism and infections were common but did not have an impact on OS. CONCLUSIONS: A hospital-based electronic informatics center provides comparable OS results, even though adverse events were frequently observed in the present study.
PURPOSE: Treatment for patients with metastatic colorectal cancer is chemotherapy commonly combined with monoclonal antibodies against vascular endothelial growth factor (bevacizumab) or epidermal growth factor receptor (cetuximab or panitumumab), the efficacy of which has been proven in randomized controlled trials. The objective of the current retrospective study was to analyze the impact of targeted therapy, adverse events, and dose reduction on overall survival (OS) and metastasis resection rates. METHODS: A hospital-based electronic informatics center was used to gather clinical data and outcome information in a "real-life" setting in a single academic hospital. A total of 178 patients were included in 2010-2013. RESULTS: In patients whose tumors expressed the KRAS wild type, the longest median OS was observed with irinotecan-based chemotherapy combined with bevacizumab (38 months), or with cetuximab (41 months). In the KRAS-mutated group, the longest median OS was observed with oxaliplatin with or without bevacizumab (34 months). Beneficial liver metastasis resections were observed in 12 out of 20 patients. Patients with KRAS wild-type tumors who received cetuximab were the most likely to undergo surgery. Age was a negative predictor of OS. Patients whose chemotherapy dose was reduced to below 80% had lower OS compared to those remaining above 80%. Treatment delays in chemotherapy did not affect OS. Pulmonary embolism and infections were common but did not have an impact on OS. CONCLUSIONS: A hospital-based electronic informatics center provides comparable OS results, even though adverse events were frequently observed in the present study.
Authors: Jean-Yves Douillard; Salvatore Siena; James Cassidy; Josep Tabernero; Ronald Burkes; Mario Barugel; Yves Humblet; György Bodoky; David Cunningham; Jacek Jassem; Fernando Rivera; Ilona Kocákova; Paul Ruff; Maria Błasińska-Morawiec; Martin Šmakal; Jean-Luc Canon; Mark Rother; Kelly S Oliner; Michael Wolf; Jennifer Gansert Journal: J Clin Oncol Date: 2010-10-04 Impact factor: 44.544
Authors: Jean-Yves Douillard; Kelly S Oliner; Salvatore Siena; Josep Tabernero; Ronald Burkes; Mario Barugel; Yves Humblet; Gyorgy Bodoky; David Cunningham; Jacek Jassem; Fernando Rivera; Ilona Kocákova; Paul Ruff; Maria Błasińska-Morawiec; Martin Šmakal; Jean Luc Canon; Mark Rother; Richard Williams; Alan Rong; Jeffrey Wiezorek; Roger Sidhu; Scott D Patterson Journal: N Engl J Med Date: 2013-09-12 Impact factor: 91.245
Authors: Eric Van Cutsem; Claus-Henning Köhne; István Láng; Gunnar Folprecht; Marek P Nowacki; Stefano Cascinu; Igor Shchepotin; Joan Maurel; David Cunningham; Sabine Tejpar; Michael Schlichting; Angela Zubel; Ilhan Celik; Philippe Rougier; Fortunato Ciardiello Journal: J Clin Oncol Date: 2011-04-18 Impact factor: 44.544
Authors: Eric Van Cutsem; Heinz-Josef Lenz; Claus-Henning Köhne; Volker Heinemann; Sabine Tejpar; Ivan Melezínek; Frank Beier; Christopher Stroh; Philippe Rougier; J Han van Krieken; Fortunato Ciardiello Journal: J Clin Oncol Date: 2015-01-20 Impact factor: 44.544
Authors: Volker Heinemann; Ludwig Fischer von Weikersthal; Thomas Decker; Alexander Kiani; Ursula Vehling-Kaiser; Salah-Eddin Al-Batran; Tobias Heintges; Christian Lerchenmüller; Christoph Kahl; Gernot Seipelt; Frank Kullmann; Martina Stauch; Werner Scheithauer; Jörg Hielscher; Michael Scholz; Sebastian Müller; Hartmut Link; Norbert Niederle; Andreas Rost; Heinz-Gert Höffkes; Markus Moehler; Reinhard U Lindig; Dominik P Modest; Lisa Rossius; Thomas Kirchner; Andreas Jung; Sebastian Stintzing Journal: Lancet Oncol Date: 2014-07-31 Impact factor: 41.316
Authors: Leonard B Saltz; Stephen Clarke; Eduardo Díaz-Rubio; Werner Scheithauer; Arie Figer; Ralph Wong; Sheryl Koski; Mikhail Lichinitser; Tsai-Shen Yang; Fernando Rivera; Felix Couture; Florin Sirzén; Jim Cassidy Journal: J Clin Oncol Date: 2008-04-20 Impact factor: 44.544
Authors: Herbert Hurwitz; Louis Fehrenbacher; William Novotny; Thomas Cartwright; John Hainsworth; William Heim; Jordan Berlin; Ari Baron; Susan Griffing; Eric Holmgren; Napoleone Ferrara; Gwen Fyfe; Beth Rogers; Robert Ross; Fairooz Kabbinavar Journal: N Engl J Med Date: 2004-06-03 Impact factor: 91.245
Authors: E Van Cutsem; A Cervantes; R Adam; A Sobrero; J H Van Krieken; D Aderka; E Aranda Aguilar; A Bardelli; A Benson; G Bodoky; F Ciardiello; A D'Hoore; E Diaz-Rubio; J-Y Douillard; M Ducreux; A Falcone; A Grothey; T Gruenberger; K Haustermans; V Heinemann; P Hoff; C-H Köhne; R Labianca; P Laurent-Puig; B Ma; T Maughan; K Muro; N Normanno; P Österlund; W J G Oyen; D Papamichael; G Pentheroudakis; P Pfeiffer; T J Price; C Punt; J Ricke; A Roth; R Salazar; W Scheithauer; H J Schmoll; J Tabernero; J Taïeb; S Tejpar; H Wasan; T Yoshino; A Zaanan; D Arnold Journal: Ann Oncol Date: 2016-07-05 Impact factor: 32.976